Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPATHY: PAE vs Pharmacotherapy for BPH
NCT04245566Phase 3Not yet recruiting
- Start
- Sep 2021
- Primary completion
- Dec 2022
01
Overview
Phase 3, randomised, open-label trial in benign prostatic hyperplasia (BPH) (2 arms). Primary endpoint: International Prostate Symptom Score at 24 months. Planned start Sep 2021; status: not yet recruiting.
02
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04245566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245566.